Episode Details

Back to Episodes
Scientists Found a New Abnormality Inside Human Glaucoma Nerve Cells — Could It Lead to a New Treatment?

Scientists Found a New Abnormality Inside Human Glaucoma Nerve Cells — Could It Lead to a New Treatment?

Published 2 months, 1 week ago
Description

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/scientists-found-a-new-abnormality-inside-human-glaucoma-nerve-cells-could-it-lead-to-a-new-treatment

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

Scientists Found a New Abnormality Inside Human Glaucoma Nerve Cells — Could It Lead to a New Treatment? Short answer: Possibly—but the evidence is still early. A newly published human donor-retina study found that glaucoma was associated with less sphingomyelin inside retinal ganglion cells, more acid sphingomyelinase protein, and greater activity of the lysosomal form of that enzyme. The study also found more retinal ganglion cells containing ceramide aggregates, although total ceramide was not significantly higher overall. That pattern is biologically interesting because acid sphingomyelinase can break down sphingomyelin into ceramide. Excessive or mislocalized ceramide can disturb lysosomes, cell membranes, autophagy, mitochondria, inflammatory signaling, and programmed cell death. However, the human study is observational and postmortem. It does not prove that acid sphingomyelinase starts glaucoma or that inhibiting it will preserve vision. The strongest evidence for causality still comes from animal and cell studies, not from patients. > My overall interpretation: Acid sphingomyelinase is a credible contributor to retinal ganglion-cell injury in at least a subset of glaucoma, but it is unlikely to be the only cause or a universal treatment target. --- What the New Human Study Actually Found The newest study, published online on August 31, 2026, examined donated human retinas from people with and without a glaucoma diagnosis. It used a sphingomyelin-binding probe called enhanced green fluorescent protein-conjugated non-toxic lysenin and identified retinal ganglion cells using the retinal ganglion-cell marker RNA-binding protein with multiple splicing. The researchers also measured acid sphingomyelinase, neutral sphingomyelinase, sphingomyelin synthase 1, sphingomyelin synthase 2, enzyme activity, and ceramide distribution. Human glaucoma donor-retina study () What can be determined from the currently accessible report? For the full table, please open this article on visualfieldtest.com. The article is currently labeled an early accepted version that may undergo further editing before the final version of record. Therefore, exact numeric values should be taken from the full downloadable article and supplementary data once they are accessible in a stable form, rather than reconstructed from figures or secondary summaries. Scientific Reports article page () The most important negative finding The study did not show a simple, uniform increase in total ceramide throughout the retina. That matters. A straightforward model would predict: > More acid sphingomyelinase → less sphingomyelin → more total ceramide. Instead, the study found: > Less sphingomyelin in retinal ganglion cells → more acid sphingomyelinase → more ceramide-containing aggregates, but no statistically significant increase in total retinal ganglion-cell ceramide. This suggests that the important abnormality may be local ceramide clustering, rather than a large increase in the average ceramide concentration across the whole retina. That is biologically plausible because ceramide can act as a membrane-organizing signal. A small amount concentrated in the wrong lysosomal or plasma-membrane domain may be more damaging than a larger amount dispersed throughout the cell. --- Why the Study Is Int

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us